Investor profile
Alexandria Venture Investments
CVC
See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
Alexandria Venture Investments is the strategic venture capital platform of Alexandria Real Estate Equities, Inc. (NYSE: ARE). Since 1996, it has provided strategic investment capital to seed-, early-, and growth-stage companies focused on novel, breakthrough discoveries in biopharma, diagnostics, research tools, agtech, digital health, and technology. The firm is uniquely positioned to fund transformative companies by combining deep scientific expertise, long-term relationships with leading investors, and a world-class international scientific advisory network — all reinforced by its parent company's ecosystem of collaborative life science campuses in AAA innovation cluster locations. Alexandria Venture Investments invests in highly disruptive companies pioneering cutting-edge therapeutic platforms that respond to the urgent needs of patients worldwide, with the ultimate mission to advance human health by curing disease and improving nutrition. The firm has been recognized as the #1 most active corporate investor in biopharma by Silicon Valley Bank for six consecutive years, and as a top-five most active U.S. investor in agrifoodtech by AgFunder for three consecutive years.
Notable quotes
“Our investment thesis remains 'go long on ag' because it is imperative to provide investment capital to disruptive companies solving these pressing and difficult challenges. Venture capital is a critical enabler of the innovation needed to address the food and agriculture challenges facing our world.”
“We focus on identifying the most intriguing and potentially meaningful translational science coming out of NYC's world-renowned academic medical institutions and across the local ecosystem that will address large unmet medical needs such as cancer, neurodegenerative and psychiatric disorders, cardio-metabolic conditions, as well as heritable and other genetically defined diseases.”
“Alexandria has long understood that the agricultural and climate innovation sectors represent perhaps the most critically untapped source of opportunities for improving nutrition, ending global hunger, combating climate change and advancing human health at its most fundamental level.”
Team
Joel S. Marcus
Executive Chairman & Founder, Alexandria Real Estate Equities / Head of Alexandria Venture Investments
Jenna Foger
Senior Vice President, Science & Technology
David Peng
Investment Team Member
Monica Beam
Vice President
Jeff Stevens
Vice President
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Proxima | Seed | $80m | 2026-01-13 |
| TRex Bio | Series B Extension | $50m | 2026-01-27 |
| Precede Biosciences | Series B | $84m | 2026-01-12 |
| Dualitas Therapeutics | Series A | $65m | 2025-09-01 |
| Mirador Therapeutics | Series A | $400m | 2024-03-01 |
| Relay Therapeutics | Series C | $400m | 2018-01-01 |
| Alnylam Pharmaceuticals | Early Stage | — | — |
| Moderna | Early Stage | — | — |
| Intra-Cellular Therapies | Series A | — | 2002-01-01 |
| Benson Hill Biosystems | Series C | $60m | 2018-01-01 |
Frequent co-investors
| VC firm | Deals together |
|---|---|
| ARCH Venture Partners | 17 |
| 5AM Ventures | 10 |
| OrbiMed | 8 |
| Atlas Venture | 7 |
| GV (Google Ventures) | 6 |
| Polaris Partners | 5 |
Fit check
Is Alexandria Venture Investments a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit